MRX vs. BGC, SNEX, FRGE, TOP, GSIW, CME, ICE, NDAQ, TW, and TROW
Should you be buying Medicis Pharmaceutical stock or one of its competitors? The main competitors of Medicis Pharmaceutical include BGC Group (BGC), StoneX Group (SNEX), Forge Global (FRGE), TOP Financial Group (TOP), Garden Stage (GSIW), CME Group (CME), Intercontinental Exchange (ICE), Nasdaq (NDAQ), Tradeweb Markets (TW), and T. Rowe Price Group (TROW). These companies are all part of the "security & commodity brokers, dealers, exchanges & services" industry.
Medicis Pharmaceutical vs.
Medicis Pharmaceutical (NYSE:MRX) and BGC Group (NASDAQ:BGC) are both mid-cap finance companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings, community ranking and institutional ownership.
BGC Group received 165 more outperform votes than Medicis Pharmaceutical when rated by MarketBeat users. However, 67.67% of users gave Medicis Pharmaceutical an outperform vote while only 59.74% of users gave BGC Group an outperform vote.
BGC Group has a net margin of 5.49% compared to Medicis Pharmaceutical's net margin of 0.00%. BGC Group's return on equity of 47.68% beat Medicis Pharmaceutical's return on equity.
Medicis Pharmaceutical pays an annual dividend of $0.56 per share and has a dividend yield of 1.6%. BGC Group pays an annual dividend of $0.08 per share and has a dividend yield of 0.8%. BGC Group pays out 32.0% of its earnings in the form of a dividend.
In the previous week, BGC Group had 1 more articles in the media than Medicis Pharmaceutical. MarketBeat recorded 1 mentions for BGC Group and 0 mentions for Medicis Pharmaceutical. BGC Group's average media sentiment score of 0.10 beat Medicis Pharmaceutical's score of 0.00 indicating that BGC Group is being referred to more favorably in the news media.
Medicis Pharmaceutical has higher earnings, but lower revenue than BGC Group.
52.1% of BGC Group shares are owned by institutional investors. 26.3% of BGC Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Medicis Pharmaceutical currently has a consensus target price of $33.25, suggesting a potential downside of 4.41%. Given Medicis Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe Medicis Pharmaceutical is more favorable than BGC Group.
Summary
BGC Group beats Medicis Pharmaceutical on 10 of the 18 factors compared between the two stocks.
Get Medicis Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medicis Pharmaceutical Competitors List
Related Companies and Tools
This page (NYSE:MRX) was last updated on 1/21/2025 by MarketBeat.com Staff
